Dendritic cell vaccine of gliomas: challenges from bench to bed

Gliomas account for the majority of brain malignant tumors. As the most malignant subtype of glioma, glioblastoma (GBM) is barely effectively treated by traditional therapies (surgery combined with radiochemotherapy), resulting in poor prognosis. Meanwhile, due to its “cold tumor” phenotype, GBM fails to respond to multiple immunotherapies. As its capacity to prime T cell response, dendritic cells (DCs) are essential to anti-tumor immunity. In recent years, as a therapeutic method, dendritic cell vaccine (DCV) has been immensely developed. However, there have long been obstacles that limit the use of DCV yet to be tackled. As is shown in the following review, the role of DCs in anti-tumor immunity and the inhibitory effects of tumor microenvironment (TME) on DCs are described, the previous clinical trials of DCV in the treatment of GBM are summarized, and the challenges and possible development directions of DCV are analyzed.

• Publication year

  2023

• Venue

  Frontiers in Immunology

• Publication date

  2023-09-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fimmu.2023.1259562PMID 37781367PMCID 10536174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy

  2023cited by this paper
• Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

  2022cited by this paper
• Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

  2022cited by this paper
• Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

  2022cited by this paper
• Dysfunctional dendritic cells limit antigen-specific T cell response in glioma

  2022cited by this paper
• Type I interferon induces cancer stem cells-mediated chemotherapy resistance

  2022cited by this paper
• Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions

  2022cited by this paper
• Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions

  2022cited by this paper
• Evasion before invasion: Pre-cancer immunosurveillance

  2021cited by this paper
• Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary.

  2021cited by this paper
• Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

  2021cited by this paper
• Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients

  2021cited by this paper
• Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion

  2021cited by this paper
• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

  2021cited by this paper
• Double-edged effects of interferons on the regulation of cancer-immunity cycle

  2021cited by this paper
• The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment

  2021cited by this paper
• Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B

  2021cited by this paper
• CD27 expression on Treg cells limits immune responses against tumors

  2021cited by this paper
• PD-L1 as a biomarker of response to immune-checkpoint inhibitors

  2021cited by this paper
• Current FDA-Approved Therapies for High-Grade Malignant Gliomas

  2021cited by this paper
• A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials

  2021cited by this paper
• The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive anti-tumor immunity in the brain

  2021cited by this paper
• The Role of Macrophages in Cancer Development and Therapy

  2021cited by this paper
• Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients

  2020cited by this paper
• Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

  2020cited by this paper
• Immunotherapy with NK cells: recent developments in gene modification open up new avenues

  2020cited by this paper
• Radiation dose-escalation and dose-fractionation modulate the immune microenvironment, cancer stem cells and vasculature in experimental high-grade gliomas.

  2020cited by this paper
• Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.

  2020cited by this paper
• Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy

  2020cited by this paper
• IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice

  2020cited by this paper
• Antitumour dendritic cell vaccination in a priming and boosting approach

  2020cited by this paper
• Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma

  2020influential reference
• Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

  2020cited by this paper
• Heterogeneity

  2020cited by this paper
• An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

  2020cited by this paper
• IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer

  2020cited by this paper
• A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

  2019cited by this paper
• Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

  2019cited by this paper
• Dendritic cells in cancer immunology and immunotherapy

  2019influential reference
• SLAMF9 regulates pDC homeostasis and function in health and disease

  2019cited by this paper
• Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production.

  2019cited by this paper
• Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

  2019cited by this paper
• Brain immunology and immunotherapy in brain tumours

  2019influential reference
• Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity.

  2019cited by this paper
• FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

  2019cited by this paper
• Trial watch: dendritic cell vaccination for cancer immunotherapy

  2019cited by this paper
• Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells

  2019cited by this paper
• Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

  2019cited by this paper
• Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression

  2019cited by this paper
• Genetic and molecular epidemiology of adult diffuse glioma

  2019cited by this paper
• Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy

  2019cited by this paper
• The Acidic Tumor Microenvironment as a Driver of Cancer.

  2019cited by this paper
• Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity

  2019cited by this paper
• A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials

  2019cited by this paper
• Tumor-associated macrophages: an accomplice in solid tumor progression

  2019cited by this paper
• Type I interferons and dendritic cells in cancer immunotherapy.

  2019cited by this paper
• Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment

  2018cited by this paper
• Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial

  2018cited by this paper
• Plasmacytoid dendritic cell in immunity and cancer.

  2018cited by this paper
• Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells

  2018cited by this paper
• Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

  2018cited by this paper
• First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

  2018cited by this paper
• Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment

  2018cited by this paper
• Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme

  2018cited by this paper
• Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma

  2018cited by this paper
• Human dendritic cell subsets: an update

  2018cited by this paper
• PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma

  2018cited by this paper
• CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature

  2018cited by this paper
• Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial

  2018cited by this paper
• The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity

  2018cited by this paper
• Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking

  2018cited by this paper
• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

  2018cited by this paper
• Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas

  2017cited by this paper
• The Microenvironmental Landscape of Brain Tumors.

  2017cited by this paper
• Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas

  2017cited by this paper
• Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide

  2017influential reference
• Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

  2017cited by this paper
• Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

  2017cited by this paper
• The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells

  2017cited by this paper
• Myeloid-Derived Suppressor Cells

  2017cited by this paper
• Systematic review and meta-analysis.

  2017cited by this paper
• Nrf2 suppresses the function of dendritic cells to facilitate the immune escape of glioma cells

  2017cited by this paper
• Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma.

  2017cited by this paper
• Tissue‐Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression

  2017cited by this paper
• Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors

  2017cited by this paper
• Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

  2017influential reference
• Hypermutations in gliomas: a potential immunotherapy target.

  2017cited by this paper
• The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity

  2016cited by this paper
• Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives.

  2016cited by this paper
• Characterization of Arginase Expression in Glioma-Associated Microglia and Macrophages

  2016cited by this paper
• Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid

  2016cited by this paper
• Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach

  2016cited by this paper
• Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma

  2016cited by this paper
• Cancer Stem Cell‐Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion

  2016cited by this paper
• Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.

  2016cited by this paper
• Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

  2015cited by this paper
• Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients With Glioma But Predominance of CD15-Positive Myeloid-Derived Suppressor Cells in Glioma Tissue

  2015cited by this paper
• Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow

  2015cited by this paper
• The role of microglia and macrophages in glioma maintenance and progression

  2015cited by this paper
• Whole Tumor Antigen Vaccines: Where Are We?

  2015cited by this paper

• Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM)

  2025cites this paper
• Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment

  2025cites this paper
• Research progress on the role of dendritic cells in glioma during 1992-2024: a bibliometric analysis

  2025cites this paper
• Dendritic cell-derived biomimetic vesicles as cancer vaccine platforms for melanoma immunotherapy.

  2025cites this paper
• Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy

  2024cites this paper
• Orexin‐A mediates glioblastoma proliferation inhibition by increasing ferroptosis triggered by unstable iron pools and GPX4 depletion

  2024cites this paper
• A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence

  2024cites this paper
• World Journal of Clinical Oncology

  year unknowncites this paper